open access

Vol 11, No 1 (2015)
Guidelines / Expert consensus
Published online: 2015-03-12
Get Citation

The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society

Maciej Krzakowski, Piotr Wysocki, Jacek Jassem, Krzysztof Krzemieniecki, Piotr Potemski, Rafał Zyśk
Onkol. Prak. Klin 2015;11(1):9-15.

open access

Vol 11, No 1 (2015)
EXPERTS' OPINION
Published online: 2015-03-12

Abstract

Rapid development of new medical technologies and inability of their full financing by a public payer necessitates searching for solutions identifying most valuable methods. This issue is particularly relevant in relation to anticancer drugs. Competent authorities (Ministry of Health, National Health Fund, Agency for Health Technology Assessment and Pricing) in Poland often use expert opinions in decision making process regarding new anticancer drugs. In order to make this process more objective, the experts from the Polish Society of Clinical Oncology and Polish Oncological Society — based on the systems used in the United Kingdom and Switzerland — developed an algorithm that quantifies the key aspects of the efficacy, safety, quality of evidence and cost-effectiveness. Based on these criteria a new anticancer compound is qualified into one of five categories considering its the added value in relation to current reimbursed standard practice.

Abstract

Rapid development of new medical technologies and inability of their full financing by a public payer necessitates searching for solutions identifying most valuable methods. This issue is particularly relevant in relation to anticancer drugs. Competent authorities (Ministry of Health, National Health Fund, Agency for Health Technology Assessment and Pricing) in Poland often use expert opinions in decision making process regarding new anticancer drugs. In order to make this process more objective, the experts from the Polish Society of Clinical Oncology and Polish Oncological Society — based on the systems used in the United Kingdom and Switzerland — developed an algorithm that quantifies the key aspects of the efficacy, safety, quality of evidence and cost-effectiveness. Based on these criteria a new anticancer compound is qualified into one of five categories considering its the added value in relation to current reimbursed standard practice.

Get Citation

Keywords

new anticancer drugs, financial abilities, objective assessment of systemic treatment modalities

About this article
Title

The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 1 (2015)

Article type

Guidelines / Expert consensus

Pages

9-15

Published online

2015-03-12

Bibliographic record

Onkol. Prak. Klin 2015;11(1):9-15.

Keywords

new anticancer drugs
financial abilities
objective assessment of systemic treatment modalities

Authors

Maciej Krzakowski
Piotr Wysocki
Jacek Jassem
Krzysztof Krzemieniecki
Piotr Potemski
Rafał Zyśk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl